CA2967350C - Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof - Google Patents

Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof Download PDF

Info

Publication number
CA2967350C
CA2967350C CA2967350A CA2967350A CA2967350C CA 2967350 C CA2967350 C CA 2967350C CA 2967350 A CA2967350 A CA 2967350A CA 2967350 A CA2967350 A CA 2967350A CA 2967350 C CA2967350 C CA 2967350C
Authority
CA
Canada
Prior art keywords
antibody
humanized
cells
bispecific antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967350A
Other languages
English (en)
French (fr)
Other versions
CA2967350A1 (en
Inventor
Soldano Ferrone
Nai-Kong V. Cheung
Ming Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Memorial Sloan Kettering Cancer Center
Original Assignee
General Hospital Corp
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Memorial Sloan Kettering Cancer Center filed Critical General Hospital Corp
Publication of CA2967350A1 publication Critical patent/CA2967350A1/en
Application granted granted Critical
Publication of CA2967350C publication Critical patent/CA2967350C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2967350A 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof Active CA2967350C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462078849P 2014-11-12 2014-11-12
US62/078,849 2014-11-12
PCT/US2015/060465 WO2016077638A1 (en) 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CA2967350A1 CA2967350A1 (en) 2016-05-19
CA2967350C true CA2967350C (en) 2021-11-23

Family

ID=55955081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2967350A Active CA2967350C (en) 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

Country Status (6)

Country Link
US (1) US11091547B2 (enExample)
EP (1) EP3218413A4 (enExample)
JP (1) JP6779873B2 (enExample)
AU (1) AU2015346205B2 (enExample)
CA (1) CA2967350C (enExample)
WO (1) WO2016077638A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015080981A1 (en) 2013-11-27 2015-06-04 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
AU2019287676A1 (en) 2018-06-13 2021-01-07 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
CN111575241B (zh) * 2020-05-29 2022-09-13 复旦大学附属眼耳鼻喉科医院 一种嵌合硫酸软骨素蛋白多糖4受体的t淋巴细胞及其制备方法和用途
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
JP2023532347A (ja) * 2020-06-29 2023-07-27 セル メディカ，インコーポレイテッド キメラ抗原受容体の緊張性シグナル伝達を減少させる方法および組成物
CN114249832B (zh) * 2020-09-24 2023-11-10 博源润生医药（杭州）有限公司 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
IL308809A (en) * 2021-06-04 2024-01-01 Amgen Res Munich Gmbh T cell binding compounds and their uses
WO2023107538A2 (en) * 2021-12-07 2023-06-15 Regents Of The University Of Minnesota Binders of chondroitin sulfate proteoglycan (cspg4) polypeptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
CA2682382A1 (en) 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
JP2012503203A (ja) 2008-09-19 2012-02-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体
CA2737597C (en) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
WO2011009090A1 (en) * 2009-07-16 2011-01-20 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
PL2483310T3 (pl) * 2009-09-29 2015-01-30 Roche Glycart Ag Bispecyficzne przeciwciała agonistyczne dla receptora śmierci
NZ603581A (en) * 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
WO2012075327A1 (en) 2010-12-02 2012-06-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods for treating a tumor using an antibody that specifically binds grp94
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
EP2850106B1 (en) 2012-05-18 2022-03-23 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
CN110437337B (zh) * 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
US20160015749A1 (en) * 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
WO2014165644A2 (en) 2013-04-04 2014-10-09 The General Hospital Corporation Combination treatments with sonic hedgehog inhibitors

Also Published As

Publication number Publication date
WO2016077638A1 (en) 2016-05-19
JP2017537082A (ja) 2017-12-14
AU2015346205B2 (en) 2021-07-29
AU2015346205A1 (en) 2017-06-01
EP3218413A1 (en) 2017-09-20
CA2967350A1 (en) 2016-05-19
US20170342151A1 (en) 2017-11-30
US11091547B2 (en) 2021-08-17
EP3218413A4 (en) 2018-03-28
JP6779873B2 (ja) 2020-11-04

Similar Documents

Publication Publication Date Title
AU2015346205B2 (en) Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
US11981742B2 (en) Antibody agents specific for human CD19 and uses thereof
US20240150464A1 (en) Materials and methods for modulating t cell mediated immunity
EP3105252B1 (en) Bispecific antibodies for use in stem cell transplantation
KR102089114B1 (ko) 항원 결합 단백질 및 암의 치료를 위한 어드레싱 산물로서 그의 용도
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
CN108495864A (zh) 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法
CA2999385A1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
RU2773317C2 (ru) Антительные агенты, специфичные к cd19 человека, и их применения
HK40071400B (en) Antibody agents specific for human cd19 and uses thereof
HK40071400A (en) Antibody agents specific for human cd19 and uses thereof
HK1241907B (en) Antibody agents specific for human cd19 and uses thereof
HK1241907A1 (en) Antibody agents specific for human cd19 and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201014

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250514